Therapeutics on target:
Attacking cancer at the source



PanTher Therapeutics is a clinical-stage oncology company working to revolutionize the treatment of solid tumors.

Our minimally invasive implantable modality provides targeted and sustained localized cancer therapy, precisely directed at the intended site. 

Our mission is to revolutionize cancer care with a proprietary treatment platform designed to enhance therapeutic response with minimal side effects.
​PanTher is led by a multidisciplinary group of entrepreneurs, clinicians, researchers, engineers and business people.
Oct. 2021 - PanTher doses first two patients in Phase1 Trial of PTM-101
Aug. 2021 - PanTher gets approval to initiate Phase1 Trial in Australia and hires experienced CMO 
  • twitter-4-xxl
  • linkedin-4-xxl
  • email-14-xxl